Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Pre-Mkt 03-12 05:21:44 EDT

431.53

-1.25

-0.29%

High438.00	Low426.04	Vol281.27K
Open427.95	D1 Closing432.78	Amplitude2.76%
Mkt Cap9.90B	Tradable Cap4.75B	Total Shares22.94M
T/O121.37M	T/O Rate2.56%	Tradable Shares11.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":431.53,"timestamp":1773259200000,"preClose":432.78,"halted":0,"volume":281270,"delay":0,"changeRate":-0.002888303526040945,"floatShares":11000087,"shares":22939969,"eps":-12.850138,"marketStatus":"Pre-Mkt","change":-1.25,"latestTime":"03-12 05:21:44 EDT","open":427.95,"high":438,"low":426.035,"amount":121366739.285,"amplitude":0.027647,"askPrice":455.99,"askSize":7,"bidPrice":406.32,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-12.850138,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773322200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":431.53,"postHourTrading":{"tag":"盘后","latestPrice":431.53,"preClose":431.53,"latestTime":"19:46 EDT","volume":2014,"amount":869142.93,"timestamp":1773272803905,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9016040844078894,"impliedVol":0.5144,"impliedVolPercentile":0.188},"requestUrl":"/m/hq/s/MDGL/wiki","defaultTab":"wiki","newsList":[{"id":"2617561306","title":"Madrigal Pharmaceuticals EVP and CFO Mardi Dier Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617561306","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617561306?lang=en_us&edition=fundamental","pubTime":"2026-03-07 08:19","pubTimestamp":1772842751,"startTime":"0","endTime":"0","summary":"Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260307:nNDLb7tbjL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Madrigal Pharmaceuticals EVP and CFO Mardi Dier Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","MDGL","BK4588"],"gpt_icon":0},{"id":"2617576880","title":"Madrigal Pharmaceuticals grants inducement equity awards to 20 new employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2617576880","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617576880?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:07","pubTimestamp":1772744863,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted equity inducement awards to 20 new non-executive employees under its 2025 Inducement Plan. The grants included options to purchase 789 shares at an exercise price of $432.00 per share and 6,882 time-based restricted stock units. The options vest 25% after one year and then 6.25% quarterly thereafter, while the restricted stock units vest in four equal annual installments over four years, subject to continued employment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL20P504:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014021.USD","NDAQ","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014005.SGD","BK4588","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","LU2210150020.SGD","MDGL","BK4139","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2613114817","title":"Madrigal Pharmaceuticals to Participate in TD Cowen 46th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613114817","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613114817?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:03","pubTimestamp":1771938232,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals to Participate in TD Cowen 46th Annual Health Care Conference               Madrigal Pharmaceuticals Inc. will participate in the TD Cowen 46th Annual Health Care Conference o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL2LT59g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","BK4112","MDGL","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","LU2210149790.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4588","LU0314104364.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2613773254","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2613773254","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613773254?lang=en_us&edition=fundamental","pubTime":"2026-02-24 03:23","pubTimestamp":1771874584,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) is back in focus after reporting full-year 2025 results, combining nearly US$1 billion in Rezdiffra sales with a net loss of US$288.28 million and an improving per-share loss.\nSee our latest analysis for Madrigal Pharmaceuticals.\nThe recent full year 2025 update comes after a sharp pullback in the share price, with a 30 day share price return of 9.46% and a 90 day share price return of a 26.52% decline. However, longer term total shareholder returns of 35.04%...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2613220545","title":"Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613220545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613220545?lang=en_us&edition=fundamental","pubTime":"2026-02-22 20:16","pubTimestamp":1771762603,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle maintained a Buy rating on Madrigal Pharmaceuticals on February 20 and set a price target of $964.00. The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","MDGL","BK4139"],"gpt_icon":0},{"id":"2612262527","title":"Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2612262527","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612262527?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:11","pubTimestamp":1771593060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 08:11 ET (13:11 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"gpt_icon":0},{"id":"2612226419","title":"Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2612226419","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612226419?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:26","pubTimestamp":1771590361,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $529 from $570 and keeps a Neutral rating on the shares. Following quart...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-lowered-to-529-from-570-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-lowered-to-529-from-570-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2612223982","title":"Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2612223982","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612223982?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:15","pubTimestamp":1771539322,"startTime":"0","endTime":"0","summary":"Analyst Ritu Baral of TD Cowen maintained a Buy rating on Madrigal Pharmaceuticals, retaining the price target of $644.00. Ritu Baral has given his...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/madrigal-pharmaceuticals-rezdiffras-strong-launch-expanding-prescriber-adoption-and-advancing-pipeline-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/madrigal-pharmaceuticals-rezdiffras-strong-launch-expanding-prescriber-adoption-and-advancing-pipeline-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"1129606368","title":"Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1129606368","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129606368?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:46","pubTimestamp":1771512378,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals' stock experienced a sharp decline in pre-market trading, plummeting 8.75% following the release of its fourth-quarter financial results.The biopharmaceutical company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MDGL"],"gpt_icon":0},{"id":"2612833582","title":"BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2612833582","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612833582?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:11","pubTimestamp":1771510280,"startTime":"0","endTime":"0","summary":"BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss** Shares of drugmaker Madrigal Pharmaceuticals MDGL.O down 6% at $462.10 premarket** Co reports Q4 loss of $2.57 per share vs analysts' estimated loss of 40 cents per share - LSEG data** MDGL posts Q4 net revenue of $321.1 million vs estimates of $312.5 million** Truist Securities says \"the 12% Q4 and Q3 revenue growth reflecting consistent progress should aid in providing investor confidence that the company can continue to execute on Rezdiffra\"** As of December 31, Madrigal had cash, cash equivalents, restricted cash, and marketable securities of $988.6 million, compared with $931.3 million a year ago** In 2025, MDGL was up 88.7%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL4N3ZF0XB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","MDGL"],"gpt_icon":0},{"id":"1161698493","title":"Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1161698493","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161698493?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:24","pubTimestamp":1771503874,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals' stock experienced a significant pre-market plunge, dropping 6.41% following the release of its fourth-quarter financial results.The biopharmaceutical company reported Q4...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MDGL"],"gpt_icon":0},{"id":"2612543402","title":"Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2612543402","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612543402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:12","pubTimestamp":1771503137,"startTime":"0","endTime":"0","summary":"Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDGL"],"gpt_icon":0},{"id":"2612404089","title":"Madrigal posts FY 2025 net revenues of USD 958.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612404089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612404089?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:04","pubTimestamp":1771502648,"startTime":"0","endTime":"0","summary":"Madrigal posts FY 2025 net revenues of USD 958.4 million               Madrigal Pharmaceuticals reported Q4 2025 product revenue, net of USD 321.08 million and FY 2025 product revenue, net of USD 958.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL1W3jZ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","MDGL","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","SG9999014005.SGD","SG9999014013.SGD","BK4139","NDAQ","BK4588","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2612240402","title":"Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612240402","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612240402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:02","pubTimestamp":1771502526,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50714280/madrigal-pharmaceuticals-q4-2025-eps-2-57-misses-0-40-estimate-sales-321-083m-beat-312-490m-estimat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"gpt_icon":0},{"id":"2612404444","title":"BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2612404444","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612404444?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502450,"startTime":"0","endTime":"0","summary":"BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.57\n\n\nFeb 19 (Reuters) - Madrigal Pharmaceuticals Q4 product revenue USD 321.083 million.\n\nQ4 operating expenses USD 380.692 million\nQ4 net income USD -58.575 million\nQ4 operating income USD -59.609 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","MDGL"],"gpt_icon":0},{"id":"2612740419","title":"Madrigal Pharmaceuticals Q4 Product Revenue USD 321.083 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612740419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612740419?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDGL","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2612404117","title":"Madrigal Pharmaceuticals Q4 Net Income USD -58.575 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612404117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612404117?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4139","MDGL"],"gpt_icon":0},{"id":"2612041734","title":"Madrigal Pharmaceuticals Q4 Operating Income USD -59.609 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612041734","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612041734?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","MDGL","BK4588"],"gpt_icon":0},{"id":"2612041084","title":"Madrigal Pharmaceuticals Q4 Operating Expenses USD 380.692 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612041084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612041084?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","MDGL","BK4585","BK4139"],"gpt_icon":0},{"id":"2612556460","title":"Madrigal Pharmaceuticals Grants Equity Awards to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2612556460","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612556460?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:05","pubTimestamp":1771362347,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Inc. has granted equity awards to five new non-executive employees under its 2025 Inducement Plan. The awards comprise a total of 2,749 time-based restricted stock units, which will vest in four equal installments on each of the first through fourth anniversaries of the grant date, contingent on continued employment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL1v5dgc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014021.USD","LU2210150020.SGD","BK4585","BK4112","IE00BKPKM429.USD","LU2210149790.SGD","MDGL","SG9999014013.SGD","SG9999014039.USD","LU2095319765.USD","LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.0075},{"period":"1month","weight":-0.1162},{"period":"3month","weight":-0.2447},{"period":"6month","weight":-0.0016},{"period":"1year","weight":0.2867},{"period":"ytd","weight":-0.259}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0254},{"period":"3month","weight":-0.0186},{"period":"6month","weight":0.0288},{"period":"1year","weight":0.2166},{"period":"ytd","weight":-0.0082}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.2,"avgChangeRate":-0.034141},{"month":4,"riseRate":0.555556,"avgChangeRate":0.008622},{"month":5,"riseRate":0.333333,"avgChangeRate":0.130548},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032539},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.07894},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction